Seroprevalence and Placental Transmission of Maternal Antibodies Specific for Neisseria meningitidis Serogroups A, C, Y and W135 and Influence of Maternal Antibodies on the Immune Response to a Primary Course of MenACWY-CRM Vaccine in the United Kingdom

Blanchard-Rohner, Géraldine; Snape, Matthew D.; Kelly, Dominic F.; O’Connor, Daniel; John, Tessa M.; Kibwana, Elizabeth; Parks, Hannah; Ford, Karen; Dull, Peter; Pollard, Andrew J.

doi:10.1097/inf.0b013e318292f425

Cited by 14 publications

(17 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the same study, there was no consistent impact of maternal antibodies on the immune response of infants to MenACWY-CRM vaccination. Despite a moderate association between MenC hSBA at 2 months and a reduced post-dose 2 MenC hSBA level, 90% of infants achieved protective hSBA titers for MenC after the second MenACWY-CRM dose at 4 months of age [38].…”

Section: B-cell Responses and Impact Of Maternal Antibodies On Vaccinmentioning

confidence: 85%

“…A study of antibody persistence up to 5 years after 4-dose infant primary vaccination showed that around one-half of children continued to have seroprotective hSBA titers (≥1:8) for serogroups W and Y, and 26% for serogroup C, whereas hSBA titers waned rapidly for MenA (6% of children had hSBA ≥1:8 by age 5 years) ( Figure 2) [31]. Persistence of bactericidal [38] UK: United Kingdom; US: United States; DTaP-HBV-IPV: combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus vaccine; DTaP-HBV-IPV/Hib: combined hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus and Haemophilus influenzae type b conjugate vaccine; MenACWY-TT: quadrivalent meningococcal A, C, E, Y vaccine conjugated to tetanus toxoid; HAV: hepatitis A vaccine;…”

Section: Assessment Of Reactogenicity and Safetymentioning

confidence: 99%

“…Infants participating in a UK study received three doses of MenACWY-CRM at 2, 4, and 12 months of age [37,38]. A high percentage of infants had hSBA titers ≥1:4 after the second dose (69% for MenA and 95-99% for serogroups C, W, and Y) [37].…”

Section: B-cell Responses and Impact Of Maternal Antibodies On Vaccinmentioning

confidence: 99%

See 2 more Smart Citations

An update of clinical experience with the quadrivalent meningococcal ACWY-CRM conjugate vaccine

Keshavan¹,

Pellegrini²,

Vadivelu-Pechai

et al. 2018

Expert Review of Vaccines

View full text Add to dashboard Cite

Menveo, quadrivalent meningococcal ACWY-CRM conjugate vaccine, was first licensed in 2010 in the United States and has a long track record of immunogenicity and safety in all age groups, including infants from 2 months of age. Areas covered: This review presents clinical and post-marketing experience with MenACWY-CRM from 32 studies conducted in 20 countries that included individuals aged from 2 months to 75 years. Expert commentary: This decade has seen an increased number of countries reporting serogroup W ST-11 clonal complex outbreaks of invasive meningococcal disease. As infant vaccination programs targeting the meningococcus are reevaluated, the role of quadrivalent meningococcal vaccines including MenACWY-CRM will be expanded. MenACWY-CRM was immunogenic in all populations and age groups studied, regardless of country of origin. MenACWY-CRM can be coadministered with many routinely used infant, toddler and adolescent vaccines, and traveler vaccines in adults, allowing for flexible use within national immunization programs and recommendations. Antibody persistence has been demonstrated up to 5 years post vaccination in all age groups. Booster doses induced robust increases in antibody titers for all four serogroups, indicative of effective priming and induction of immunological memory. The acceptable safety profile of MenACWY-CRM has been confirmed in large post-marketing safety studies.

show abstract

Section: B-cell Responses and Impact Of Maternal Antibodies On Vaccinmentioning

confidence: 85%

Section: Assessment Of Reactogenicity and Safetymentioning

confidence: 99%

See 1 more Smart Citation

An update of clinical experience with the quadrivalent meningococcal ACWY-CRM conjugate vaccine

Keshavan¹,

Pellegrini²,

Vadivelu-Pechai

et al. 2018

Expert Review of Vaccines

View full text Add to dashboard Cite

show abstract

“…In a recent study examining the influence of maternal antibodies specific for serogroups A, C, W, and Y on infant responses to MenACWY‐CRM vaccination at 2 and 4 months of age, maternal antibody levels were low and did not associate with infant vaccine responses. However, immunizing women before or during pregnancy may increase antibody levels and subsequent placental transmission to confer increased protection to the infant …”

Section: Discussionmentioning

confidence: 99%

History of Meningococcal Outbreaks in the United States: Implications for Vaccination and Disease Prevention

2016

View full text Add to dashboard Cite

Invasive meningococcal disease caused by Neisseria meningitidis presents a significant public health concern. Meningococcal disease is rare but potentially fatal within 24 hours of onset of illness, and survivors may experience permanent sequelae. This review presents the epidemiology, incidence, and outbreak data for invasive meningococcal disease in the United States since 1970, and it highlights recent changes in vaccine recommendations to prevent meningococcal disease. Relevant publications were obtained by database searches for articles published between January 1970 and July 2015. The incidence of meningococcal disease has decreased in the United States since 1970, but serogroup B meningococcal disease is responsible for an increasing proportion of disease burden in young adults. Recent serogroup B outbreaks on college campuses warrant broader age-based recommendations for meningococcal group B vaccines, similar to the currently recommended quadrivalent vaccine that protects against serogroups A, C, W, and Y. After the recent approval of two serogroup B vaccines, the Advisory Committee on Immunization Practices first updated its recommendations for routine meningococcal vaccination to cover at-risk populations, including those at risk during serogroup B outbreaks, and later it issued a recommendation for those aged 16-23 years. Meningococcal disease outbreaks remain challenging to predict, making the optimal disease management strategy one of prevention through vaccination rather than containment. How the epidemiology of serogroup B disease and prevention of outbreaks will be affected by the new category B recommendation for serogroup B vaccines remains to be seen.

show abstract

“…129 Consequently, vaccination of pregnant women with meningococcal vaccines is recommended, if indicated.…”

Section: Vaccination Of Pregnant Womenmentioning

confidence: 99%

Recommended immunization schedules for adults: Clinical practice guidelines by the Escmid Vaccine Study Group (EVASG), European Geriatric Medicine Society (EUGMS) and the World Association for Infectious Diseases and Immunological Disorders (WAidid)

Esposito

Bonanni

Maggi

et al. 2016

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Rapid population aging has become a major challenge in the industrialized world and progressive aging is a key reason for making improvement in vaccination a cornerstone of public health strategy. An increase in age-related disorders and conditions is likely to be seen in the near future, and these are risk factors for the occurrence of a number of vaccine-preventable diseases. An improvement in infectious diseases prevention specifically aimed at adults and the elderly can therefore also decrease the burden of these chronic conditions by reducing morbidity, disability, hospital admissions, health costs, mortality rates and, perhaps most importantly, by improving the quality of life. Among adults, it is necessary to identify groups at increased risk of vaccine-preventable diseases and highlight the epidemiological impact and benefits of vaccinations using an evidence-based approach. This document provides clinical practice guidance on immunization for adults in order to provide recommendations for decision makers and healthcare workers in Europe. Although immunization is considered one of the most impactful and cost-effective public health measures that can be undertaken, vaccination coverage rates among adults are largely lower than the stated goal of 95% among adults, and stronger efforts are needed to increase coverage in this population. Active surveillance of adult vaccine-preventable diseases, determining the effectiveness of the vaccines approved for marketing in the last 5 y, the efficacy and safety of vaccines in immunocompromised patients, as well as in pregnant women, represent the priorities for future research.

show abstract

Seroprevalence and Placental Transmission of Maternal Antibodies Specific for Neisseria meningitidis Serogroups A, C, Y and W135 and Influence of Maternal Antibodies on the Immune Response to a Primary Course of MenACWY-CRM Vaccine in the United Kingdom

Cited by 14 publications

References 36 publications

An update of clinical experience with the quadrivalent meningococcal ACWY-CRM conjugate vaccine

An update of clinical experience with the quadrivalent meningococcal ACWY-CRM conjugate vaccine

History of Meningococcal Outbreaks in the United States: Implications for Vaccination and Disease Prevention

Recommended immunization schedules for adults: Clinical practice guidelines by the Escmid Vaccine Study Group (EVASG), European Geriatric Medicine Society (EUGMS) and the World Association for Infectious Diseases and Immunological Disorders (WAidid)

Contact Info

Product

Resources

About